Mesenchymal circulating tumor cells as prognostic markers in HCC Post-Transplantation: Sirolimus as a potential therapeutic Modulator

IF 3.5 2区医学 Q2 ONCOLOGY

Ejso Pub Date : 2025-05-15 DOI:10.1016/j.ejso.2025.110147

Jinyan Chen , Rongsen Wang , Huigang Li , Jiancai Sun , Ruijie Zhao , Jianyong Zhuo , Zuyuan Lin , Chiyu He , Xingzhu Chen , Jun Li , Leyi Chen , Xudong Yang , Xuyong Wei , Shusen Zheng , Xiao Xu , Di Lu

{"title":"Mesenchymal circulating tumor cells as prognostic markers in HCC Post-Transplantation: Sirolimus as a potential therapeutic Modulator","authors":"Jinyan Chen , Rongsen Wang , Huigang Li , Jiancai Sun , Ruijie Zhao , Jianyong Zhuo , Zuyuan Lin , Chiyu He , Xingzhu Chen , Jun Li , Leyi Chen , Xudong Yang , Xuyong Wei , Shusen Zheng , Xiao Xu , Di Lu","doi":"10.1016/j.ejso.2025.110147","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The prognostic value of CTCs for post-LT tumor recurrence remains insufficiently studied, and the associations between CTCs and immunosuppressants remain unclear.</div></div><div><h3>Methods</h3><div>This study analyzed 277 HCC patients undergoing liver transplantation. MCTC and ECTC levels were measured from the day of surgery to one month postoperatively. Prognostic outcomes were compared across patients with varying MCTC levels, with subgroup analysis based on the presence or absence of major portal vein tumor thrombus. Differences in MCTC dynamics and outcomes were further evaluated across immunosuppressant regimens.</div></div><div><h3>Results</h3><div>Patients with low MCTC levels demonstrated better recurrence-free survival (RFS) than those with high MCTC levels (p = 0.022), a trend observed in both the PVTT subgroup (p = 0.023) and the non-PVTT subgroup (p = 0.046). Patients with a reduction in MCTC levels at the second measurement had significantly better prognoses compared to those without a reduction (p = 0.03). The use of sirolimus was associated with a decrease in MCTC levels (p = 0.017), and patients receiving sirolimus exhibited improved survival compared to those not using sirolimus (p = 0.033). Sirolimus also extended post-recurrence survival (p = 0.0052).</div></div><div><h3>Conclusion</h3><div>MCTC levels serve as an effective predictor of tumor recurrence following liver transplantation for HCC. Sirolimus reduces MCTC levels and extends post-recurrence survival.</div></div>","PeriodicalId":11522,"journal":{"name":"Ejso","volume":"51 9","pages":"Article 110147"},"PeriodicalIF":3.5000,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ejso","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S074879832500575X","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

The prognostic value of CTCs for post-LT tumor recurrence remains insufficiently studied, and the associations between CTCs and immunosuppressants remain unclear.

Methods

This study analyzed 277 HCC patients undergoing liver transplantation. MCTC and ECTC levels were measured from the day of surgery to one month postoperatively. Prognostic outcomes were compared across patients with varying MCTC levels, with subgroup analysis based on the presence or absence of major portal vein tumor thrombus. Differences in MCTC dynamics and outcomes were further evaluated across immunosuppressant regimens.

Results

Patients with low MCTC levels demonstrated better recurrence-free survival (RFS) than those with high MCTC levels (p = 0.022), a trend observed in both the PVTT subgroup (p = 0.023) and the non-PVTT subgroup (p = 0.046). Patients with a reduction in MCTC levels at the second measurement had significantly better prognoses compared to those without a reduction (p = 0.03). The use of sirolimus was associated with a decrease in MCTC levels (p = 0.017), and patients receiving sirolimus exhibited improved survival compared to those not using sirolimus (p = 0.033). Sirolimus also extended post-recurrence survival (p = 0.0052).

Conclusion

MCTC levels serve as an effective predictor of tumor recurrence following liver transplantation for HCC. Sirolimus reduces MCTC levels and extends post-recurrence survival.

查看原文本刊更多论文

间充质循环肿瘤细胞作为HCC移植后预后标志物：西罗莫司作为潜在的治疗调节剂

背景ctc对lt后肿瘤复发的预后价值研究尚不充分，ctc与免疫抑制剂之间的关系尚不清楚。方法对277例肝移植患者进行分析。从手术当日至术后1个月测量MCTC和ECTC水平。比较不同MCTC水平患者的预后结果，并根据是否存在主要门静脉肿瘤血栓进行亚组分析。进一步评估不同免疫抑制剂方案中MCTC动态和结果的差异。结果低MCTC患者的无复发生存率（RFS）高于高MCTC患者（p = 0.022）， PVTT亚组（p = 0.023）和非PVTT亚组（p = 0.046）均有此趋势。与未降低MCTC水平的患者相比，第二次测量时MCTC水平降低的患者预后明显更好（p = 0.03）。西罗莫司的使用与MCTC水平的降低相关（p = 0.017），与未使用西罗莫司的患者相比，接受西罗莫司的患者表现出更高的生存率（p = 0.033）。西罗莫司也延长了复发后生存期（p = 0.0052）。结论mctc水平可作为肝癌肝移植术后肿瘤复发的有效预测指标。西罗莫司降低MCTC水平，延长复发后生存期。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Ejso 医学-外科

CiteScore

6.40

自引率

2.60%

发文量

1148

审稿时长

41 days

期刊介绍： JSO - European Journal of Surgical Oncology ("the Journal of Cancer Surgery") is the Official Journal of the European Society of Surgical Oncology and BASO ~ the Association for Cancer Surgery. The EJSO aims to advance surgical oncology research and practice through the publication of original research articles, review articles, editorials, debates and correspondence.